Trem-cel
Cross-source consensus on Trem-cel from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Benefits
Dosage & preparation
Preparation
Highlighted claims
- Trem-cel is an allogeneic CD34+ hematopoietic stem and progenitor cell product edited with CRISPR-Cas9 to disrupt CD33. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Trem-cel is intended to protect donor-derived hematopoiesis while enabling CD33-directed therapy against residual leukemia. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Trem-cel manufacturing used CD34+ magnetic selection followed by electroporation with a CD33-targeted CRISPR-Cas9 ribonucleoprotein. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The median manufactured trem-cel dose was 8.01 x 10^6 CD34+ cells per kg and the median CD33 editing efficiency was 90%. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Trem-cel achieved rapid neutrophil and platelet engraftment in the treated patients. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The study found no evidence that CD33 deletion impaired hematopoiesis, immune reconstitution, or neutrophil oxidative burst function. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial